Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 37-44

  Noel, Gary J ^a   Strauss, Richard S ^a   Amsler, Karen ^a   Heep, Markus ^b   Pypstra, Rienk ^b   Solomkin, Joseph S ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; VANCOMYCIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EOSINOPHILIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFECTION COMPLICATION; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHILIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN INFECTION; TASTE DISORDER; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOPHILIA; URIC ACID BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DOUBLE-BLIND METHOD; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MALE; MIDDLE AGED; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME; VANCOMYCIN;

EID: 37849009009     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00551-07     Document Type: Article

References (31)

1. Andes, D. R., and W. A. Craig. 2000. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1079.
2. Anonymous. 1998. Guidance for industry. Uncomplicated and complicated skin and skin structure infections: developing antimicrobial drugs for treatment. Food and Drug Administration, Washington, DC. http://www.fda.gov/cder/guidance/2566dft.pdf.
3. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681.
4. Azoulay-Dupuis, E., J. P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111.
5. Bogdanovich, T., C. Clark, L. Ednie, G. Lin, K. Smith, S. Shapiro, and P. C. Appelbaum. 2006. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50:2050-2057.
6. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
7. Carbon, C., G. B. Calandra, C. Norden, J. D. Nelson, and J. T. Mader. 1993. General guidelines for the evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure, p. 168-174. In T. R. Beam Jr., D. N. Gilbert, and C. M. Kunin (ed.), European guidelines for the clinical evaluation of anti-infective drug products. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
8. Chambers, H. F. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888.
9. CLSI. 2005. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A6. CLSI, Wayne, PA.
10. CLSI. 2005. Performance standards for antimicrobial disk susceptibility tests, 15th ed. M2-A8. CLSI, Wayne PA.
11. CLSI. 2005. Performance standards for antimicrobial susceptibility testing, 15th informational supplement. M100-S15. CLSI, Wayne, PA.
12. Denis, O., A. Deplano, C. Nonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Mendonca, and M. J. Struelens. 2006. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob. Agents Chemother. 50:2680-2685.
13. Deshpande, L. M., and R. N. Jones. 2003. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9:1120-1124.
14. Ellis-Grosse, E. J., T. Babinchak, N. Dartois, G. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5):S341-S353.
15. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
16. Halem, M., J. Trent, J. Green, and F. Kerdel. 2006. Community-acquired methicillin resistant Staphylococcus aureus skin infection. Semin. Cutan. Med. Surg. 25:68-71.
17. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
18. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
19. Kluytmans-Vandenbergh, M. F., and J. A. Kluytmans. 2006. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect. 12(Suppl. 1):9-15.
20. Kollef, M. H., and S. T. Micek. 2006. Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen? Curr. Opin. Infect. Dis. 19: 161-168.
21. Lodise, T. P., Jr., R. Pypstra, J. B. Kahn, B. P. Murthy, H. C. Kimko, K. Bush, G. J. Noel, and G. L. Drusano. 2007. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 51:2378-2387.
22. Martone, W. J., and K. C. Lamp. 2006. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr. Med. Res. Opin. 22:2337-2343.
23. McClure, J. A., J. M. Conly, V. Lau, S. Elsayed, T. Louie, W. Hutchins, and K. Zhang. 2006. Novel multiplex PCR assay for detection of the staphylococcal virulence marker Panton-Valentine leukocidin genes and simultaneous discrimination of methicillin-susceptible from -resistant staphylococci. J. Clin. Microbiol. 44:1141-1144.
24. Moran, G. J., A. Krishnadasan, R. J. Gorwitz, G. E. Fosheim, L. K. McDougal, R. B. Carey, and D. A. Talan. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
25. Mouton, J. W., A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt. 2004. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48:1713-1718.
26. Nichols, R. L., D. R. Graham, S. L. Barriere, A. Rodgers, S. E. Wilson, M. Zervos, D. L. Dunn, B. Kreter, et al. 1999. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J. Antimicrob. Chemother. 44:263-273.
27. Sanchez-Navarro, A., C. I. Colino, and M. M. Sanchez Recio. 2001. A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime. Clin. Pharmacokinet. 40: 125-134.
28. Schmitt-Hoffmann, A., M. Harsch, M. Heep, M. Schleimer, T. Brown, and A. Man. 2004. BAL5788 in patients with complicated skin and skin structure infections caused by gram-positive pathogens including methicillin-resistant Staphylococcus species (MRSS), abstr. P-1031. Abstr. 14th ECCMID.
29. Stevens, D. L., A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. Goldstein, S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya, and J. C. Wade. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406.
30. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
31. Weigelt, J., K. Itani, D. Stevens, W. Lau, M. Dryden, and C. Knirsch. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49:2260-2266.